Podcasts about Immunotherapy

How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient's treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The panel, featuring specialists from various institutions, discusses the specifics of sequencing therapies, the impact of targeted and immunotherapies, and the nuances of treating different patient profiles, including non-smokers and those with specific genetic mutations. The conversation also touches on the integration of new staging systems, the benefits of multidisciplinary clinics, and the ongoing evolution of cancer treatment trials. The discussion aims to provide clarity on the latest advancements and future directions in managing lung cancer, emphasizing the importance of tailored treatment plans and the potential of emerging technologies. --- TIMESTAMPS 00:00 - Introduction05:16 - Molecular Diagnostics and Liquid Biopsy21:43 - Targeted Therapy Options27:29 - Managing Toxicities and Treatment Strategies33:13 - Challenges with Immunotherapy in Special Cases34:07 - Lung Transplantation in Cancer Patients48:38 - Multidisciplinary Clinics and Collaboration01:06:29 - Future Directions --- RESOURCES ADAURA Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2027071 Gomez NSCLChttps://pmc.ncbi.nlm.nih.gov/articles/PMC5143183/

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nutritional strategies for treating Barrett's EsophagusHow can my uncle mitigate the side effects of his Merkel cell carcinoma therapy?How long can I take strontium?Is beet root powder beneficial for nitric oxide production?

The best water filter?Even more on gadoliniumVagus nerve therapy benefitsWith so many benefits of drinking coffee, should I drink more of it instead of tea?Any update on Barrett's Esophagus?

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Please visit answersincme.com/TDB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses optimizing care with immunotherapy for patients with MSI-H/dMMR disease. Upon completion of this activity, participants should be better able to: Discuss the efficacy and safety of immunotherapy-based regimens in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) advanced colorectal cancer (CRC); and Outline evidence-based strategies to optimize outcomes for patients with MSI-H/dMMR advanced CRC.

Send us a text

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve deep into a series of transformative events that underscore the dynamic nature of our industry, where scientific innovation meets regulatory evolution and market adaptation.We begin with significant regulatory news from Medicare, which recently announced price reductions for 15 prescription drugs, including Novo Nordisk's semaglutide products, Ozempic and Wegovy. This initiative is part of the Inflation Reduction Act aimed at making essential medications more affordable. By potentially increasing accessibility to these treatments, this move highlights a growing trend towards cost containment in drug pricing within the U.S. healthcare system. It reflects a broader effort to ensure that life-saving treatments remain within reach for more patients, emphasizing the need for balance between innovation and affordability.Turning to approvals, Otsuka has secured FDA clearance for Voyxact, a first-in-class treatment targeting IgA nephropathy (IgAN). This positions Otsuka in an increasingly competitive market space populated by major players like Novartis and Vertex. The entry of Voyxact could pave the way for innovative therapeutics in kidney diseases, offering new hope to patients who have had limited treatment options until now.On the other side of the Atlantic, French authorities have conducted a raid on Sanofi's headquarters as part of a tax fraud investigation. This development sheds light on ongoing scrutiny in the pharmaceutical sector regarding financial practices and regulatory compliance. Such investigations can have far-reaching implications on corporate governance and transparency, reminding us of the importance of ethical practices in maintaining industry trust.Novo Nordisk has strategically used its FDA national priority voucher to expedite the review process for a high-dose formulation of Wegovy. This move underscores the importance of regulatory incentives in accelerating drug development timelines, allowing for quicker patient access to potentially life-changing therapies. It's a testament to how strategic navigation through regulatory pathways can significantly impact drug availability.In clinical trials, Sarepta Therapeutics received FDA clearance to conduct a study combining its gene therapy Elevidys with sirolimus in patients with Duchenne muscular dystrophy. The study aims to address liver safety issues associated with Elevidys, which had led to previous label restrictions. This reflects the industry's commitment to enhancing therapeutic safety profiles while expanding treatment indications.In oncology advancements, AstraZeneca's Imfinzi received FDA approval for use in early-stage stomach cancer, marking its third perioperative indication. This approval underscores the expanding role of immunotherapy across various cancer types and stages, offering new treatment paradigms that could improve surgical outcomes and long-term patient survival.Despite these advances, there is skepticism regarding artificial intelligence's role in regulatory compliance submissions among pharmaceutical professionals. A survey reveals that 65% express distrust towards AI-generated outputs, highlighting challenges that AI technologies face in gaining acceptance within highly regulated environments such as pharmaceuticals. However, federal recommendations to revamp U.S. biotechnology research emphasize incorporating AI into scientific processes to maintain global competitiveness. This call reflects concerns over potential declines in innovation leadership and underscores the need for strategic investment in research infrastructure.In antitrust news, the Federal Trade Commission (FTC) outlined its case agaiSupport the show

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Hoffman continues his conversation with Alan Frost, founder of Flava Naturals, and Dr. Joseph C. Maroon, MD, FACS, clinical professor and vice chairman of the Department of Neurological Surgery and Heindl Scholar in Neuroscience at the University of Pittsburgh Medical Center, and author of "The Science of Cocoa."

Alan Frost, founder of Flava Naturals, and Dr. Joseph C. Maroon, MD, FACS, clinical professor and vice chairman of the Department of Neurological Surgery and Heindl Scholar in Neuroscience at the University of Pittsburgh Medical Center, and author of "The Science of Cocoa," detail recent scientific findings on the cardiovascular and cognitive benefits of cocoa flavanols, the importance of sourcing and processing cocoa, and how cocoa can enhance athletic performance and brain health. The episode also covers the benefits of cocoa for skin health, fighting inflammation, and even mitigating some of the effects of sitting. Dr. Maroon elaborates on his protocols for concussion recovery, including the use of omega-3 fish oil, creatine, and CBD. The episode concludes with a discussion on how cocoa impacts mood and a special discount offer for Flava Naturals products. Just go to FlavaNaturals.com and use coupon code HOFFMAN20 for 20% off site-wide, plus get free shipping on all orders over $30.

    When she began experiencing severe bruising and fatigue and turning pale in late 2013, Casey Kang sought medical attention.  This led to a diagnosis of acute lymphoblastic leukemia.  She was placed on an aggressive, 18-month chemotherapy regimen, which included doxorubicin and methotrexate.  Casey relapsed three times during which she was placed on an experimental immunotherapy.  All told, she spent 168 days in a hospital, but Casey achieved survivorship.  She is now a coach who helps women diagnosed with cancer through the physical, mental and emotional challenges that occur after treatment.   When Casey Kang experienced various aches and pains at the end of 2013, she thought they were tied to holiday- or work-related stress.  She sought medical attention, was prescribed ten days of antibiotics, and was told to return in two weeks.  During the ten days, things got worse.  She was stricken with extreme fatigue, bruising, vision issues and her turning pale.  While this went on, she continued to go to work.  She underwent blood tests, and they revealed she had leukemia.  Even before the test results came back, her care team called for a bone marrow transplant, so sure were they that she had cancer.   Casey said her cancer was subsequently diagnosed as acute lymphoblastic leukemia.  Because of its aggressive nature, she was put on an aggressive, 18-month chemotherapy regimen.  It included doxorubicin and methotrexate.  She experienced two relapses and was prescribed an experimental immunotherapy.   Multiple hospital stays totaled 168 days.  During that time, Casey learned how mentally tough she was and is.  As much as she disliked the time in the hospital, she was sure to create a routine that would get her through the day.  Casey used the hospital floor's exercise bike and walked laps around the floors, with 17 laps equaling a mile.   Despite a grueling journey, Casey Kang achieved survivorship.  She is active on social media, as she works tirelessly to aid woman diagnosed with cancer to make them physically, mentally and emotionally strong when dealing with life after treatment.  As for herself, she says her overall is better than it was before her diagnosis.   Additional Resources:   Casey's Website:   https://www.thehappierhustle.com   Casey's Free Guide:   https://casey-head.mykajabi.com/free-guide          

As part of our 2025 Board Review Course Dr. Mahmood provides insights into the contemporary state of our understanding of CAR T therapies, their CV risk, and management. You can purchase the complete set of review course videos at the link below. This includes modules covering the Management & Detection of Cardiac Dysfunction, Toxicities of Traditional Therapies, Hematology, and Immunotherapy.https://members.ic-os.org/store/viewproduct.aspx?id=26378193

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, host Shikha Jain, MD, speaks with Jason Williams, MD, and Nathan Goodyear, MD, about innovations in immunotherapy, the future of cancer care and more. •    Welcome to another exciting episode of Oncology Overdrive 1:02 •    About Williams 1:12 •    About Goodyear 1:56 •    The interview 3:08 •    Nathan, can you explain the concept of your medical philosophy, Docēre rāphè, and how you integrate it into your practice? 3:29 •    Jason, how did you get to where you are today, and how did you end up founding the Williams Cancer Institute? 5:28 •    Nathan, as an OB-GYN and lifestyle physician, what was your path to this space and at Williams Cancer Institute? 14:22 •    How do you both navigate being creative in the current climate of misinformation from a patient and physician standpoint?  20:17 •    Jason, what are the benefits and challenges of practicing in other countries versus in the United States? 26:05 •    Discussion on patient education through scientific evidence and innovation. 31:00 •    If someone could only listen to the last minute of this episode, what would you want listeners to take away? 33:37 •    How to contact Goodyear & Williams 35:42 •    Thanks for listening 36:11 Jason Williams, MD, DABR, is a medical doctor, board-certified radiologist and image-guided cancer specialist. As a leader in immunotherapy, he performed the world's first ablation procedure combined with intra-tumoral immunotherapy injections. Dr. Williams serves as the Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, which he founded to advance innovative cancer treatments. Nathan Goodyear, MD, MD(H), is an integrative medicine physician, board-certified in obstetrics and gynecology, and a leader in wellness and cancer prevention. He specializes in functional and regenerative medicine, focusing on healing and teaching the body to restore itself. Dr. Goodyear works at the Williams Cancer Institute, pioneering innovative cancer care with a holistic approach. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Goodyear and Williams can be reached at williamscancerinstitute.com. Disclosures: Jain, Goodyear and Williams report no relevant financial disclosures. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Richard Pazdur took the top job at FDA's Center for Drug Evaluation and Research after receiving vows that he would be leading CDER free from political interference. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the issues that could prove to be flashpoints between Pazdur and the heads of FDA and HHS, including personnel, RSV mAbs, puberty blockers and SSRIs.BioCentury's analysts assess bispecific innovation at the annual meeting of the Society for Immunotherapy of Cancer (SITC) and the growing field of companies pursuing RNAi, many of which have multiple unpartnered assets. Also featured in this week's episode: new funds from European VCs Medicxi and Sofinnova Partners, FDA's new plausible mechanism pathway and the Trump administration's “most favored nation” drug-pricing plan, which is turning out to be much more less onerous to drug companies than its original description suggested. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.View full story: https://www.biocentury.com/article/657631#RNAiTherapeutics #BispecificAntibodies #CD3TCellEngagers #MechanismOfAction #ImmunoOncology #PlausibleMechanismPathway #RegulatoryScience #ClinicalTranslation00:01 - Sponsor Message: Voyager Therapeutics 03:08 - FDA's Richard Pazdur13:08 - Plausible Mechanism Pathway19:30 - Most Favored Nation23:12 - Takeaways from SITC28:05 - RNAi in China33:21 - European VCsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Please visit answersincme.com/CAY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses how to optimize the use of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable high-risk melanoma. Upon completion of this activity, participants should be better able to: Recognize recurrence patterns in patients with resected high-risk melanoma and the importance of timely referral to improve recurrence-free survival; Evaluate the risk-benefit profiles of neoadjuvant, adjuvant, or perioperative immunotherapy in patients with resectable stage IIB/C and stage III/IV melanoma; and Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanoma.

Please visit answersincme.com/CAY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses how to optimize the use of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable high-risk melanoma. Upon completion of this activity, participants should be better able to: Recognize recurrence patterns in patients with resected high-risk melanoma and the importance of timely referral to improve recurrence-free survival; Evaluate the risk-benefit profiles of neoadjuvant, adjuvant, or perioperative immunotherapy in patients with resectable stage IIB/C and stage III/IV melanoma; and Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanoma.

As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We're kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS They discuss the operation of tumor boards at their respective institutions, the impact of virtual meetings, optimal strategies for mediastinal staging, the management of early-stage lung cancer, and the emerging role of ablation therapy. The conversation dives into the complexities of treating patients with recurrence or metastatic disease, highlighting the importance of collaborative decision-making in navigating these challenging scenarios. The episode emphasizes the critical role of multidisciplinary tumor boards in providing informed, patient-centered care. --- TIMESTAMPS 00:00 - Introduction06:59 - Role of Pulmonologists in Tumor Boards12:08 - Importance of Tissue Diagnosis24:52 - Lung Cancer Screening and Stigma34:01 - Interventional Radiology and Biopsies46:21 - Challenges with Immunotherapy and Radiation53:44 - The Importance of Multidisciplinary Teams54:24 - Final Thoughts --- RESOURCES American Lung Association 2024 Datahttps://www.lung.org/getmedia/12020193-7fb3-46b8-8d78-0e5d9cd8f93c/SOLC-2024.pdf National Lung Screening Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1102873 Checkmate 816https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 PACIFIC Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937

Biochemist Lingyin Li survived breast cancer at just 30 and now works to harness the human immune system to fight cancers that have long evaded treatment. T cells, she says, are powerful cancer killers, but they can be oblivious. She and her lab colleagues have discovered a masking enzyme that squelches the immune system's “danger signals” and are now developing drugs to block that enzyme. She likens her work to an arms race between cancer and immunotherapy. “The cancers are not getting smarter, but we are,” Li tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Lingyin LiConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Lingyin Li, a professor of biochemistry at Stanford University.(00:03:38) Research MotivationLingyin explains how her breast cancer diagnosis inspired her research.(00:04:31) How T-Cells WorkT-cell mechanisms and why they struggle to reach solid tumors.(00:05:38) Immune System OverviewInnate and adaptive immunity and how mutations make cancer recognizable.(00:07:28) Awakening the Immune SystemEfforts to stimulate innate immune cells to detect and expose tumors.(00:10:54) The Cancer SignalDiscovery of cancer-derived DNA signals that alert the immune system.(00:13:01) Cancer's Evasion MechanismHow tumors destroy immune signals to hide from detection.(00:14:26) ENPP1 EnzymeIdentification of ENPP1 as the enzyme enabling immune evasion.(00:15:22) Balancing Immunity and SafetyRole of ENPP1 in autoimmunity and the challenge of targeting it safely.(00:19:30) ENPP1 InhibitorsDevelopment of molecules to block ENPP1 and enhance immune signaling.(00:24:55) Preclinical FindingsThe promising results against aggressive solid tumors in animal studies(00:28:05) From Lab to ClinicThe progress toward FDA approval and preparation for human testing.(00:31:04) Future In a MinuteRapid-fire Q&A: innovation, collaboration, and the outlook for cancer treatment.(00:33:14) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

A breakthrough that could reshape cancer treatment.GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body's own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company's latest clinical progress and the potential of its lead drug candidate, GTB-3650.He also shares insights into the science behind TriKE®, the company's pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling updates that underscore the dynamic nature of our industry, marked by scientific breakthroughs, strategic shifts, regulatory advancements, and more.Starting with Pfizer's ambitious endeavors in oncology, the company has initiated Phase 3 trials for its bispecific antibody PF-08634404, targeting non-small cell lung cancer. This innovative approach aims to supersede Keytruda by simultaneously targeting the PD-1 and VEGF pathways, crucial in tumor growth and immune evasion. Pfizer is making substantial strides with its PD-1xVEGF bispecific antibodies by announcing seven near-term trials, including a pivotal phase 3 trial comparing this agent to Keytruda in non-small cell lung cancer. This underscores Pfizer's commitment to developing next-generation immunotherapies that could redefine cancer treatment paradigms by offering more targeted options. The implications are significant; by enhancing therapeutic efficacy through this dual-targeted strategy, Pfizer could set new standards in lung cancer treatment, potentially improving patient outcomes and redefining first-line therapies.Meanwhile, a strategic merger between Mallinckrodt and Endo has culminated in a $6.7 billion transaction, resulting in the rebranding of the combined entity as Keenova. This merger is particularly notable for its decision to spin off the Par Health generics business. Such a move indicates a focused shift towards specialty pharmaceuticals aimed at rare diseases—a trend increasingly seen across the industry as companies pivot towards niche markets with high unmet needs.In financing news, Vor Bio's successful $100 million public offering highlights growing investor confidence in companies addressing autoimmune diseases. This capital will likely accelerate Vor Bio's clinical-stage programs, potentially transforming patient care in this challenging therapeutic area through new and effective treatments.On the regulatory front, Glenmark's Ryaltris has secured approval from China's National Medical Products Administration for treating moderate to severe allergic rhinitis. This approval is pivotal as Glenmark expands its footprint in respiratory therapeutics with innovative small molecule therapies designed to alleviate allergy symptoms—a sign of their strategic growth within this domain.Recent clinical trial results also offer promising news. CeleCor Therapeutics' zalunfiban has shown Phase 3 success for segment elevation myocardial infarction, while UbiVac's DPV-001 has demonstrated improved survival rates in head and neck squamous cell carcinoma. Engene's Detalimogene voraplasmid exhibited a 63% response rate in bladder cancer patients unresponsive to BCG therapy. These findings reflect ongoing advances in targeted therapies and personalized medicine approaches that continue to reshape the oncology landscape.In policy changes, the UK government has unveiled a five-year roadmap aimed at replacing animal testing with AI and 3D tissue models. This initiative marks a pivotal shift towards more ethical and technologically advanced methods in drug development, potentially accelerating discovery processes while reducing reliance on animal models—a significant move that aligns with global trends towards more humane scientific practices.Meanwhile, Richard Pazdur's appointment as director of the FDA's Center for Drug Evaluation and Research signals strategic leadership changes amidst ongoing organizational investigations. His extensive experience in oncology is expected to guide regulatory oversight during this transformative period for the agency. Dr. Richard Pazdur's appointment as director of CDER representsSupport the show

You've probably heard of Oral Immunotherapy—or OIT—a treatment that's gaining attention in the food allergy world. But what's it really like to go through the process? Many families discover there's more to OIT than they expected. To help unpack the basics and offer clarity, we're talking with allergist, Dr. Brian Vickery, about what to know before beginning this journey. Resources to keep you in the know:Resources to keep you in the know:FAACT's Food Allergy Treatments SectionFAACT's Navigating Treatment Choices Section FAACT's Navigating the Food Allergy Treatment Decision ProcessYou can find FAACT's Roundtable Podcast on Apple Podcasts, Pandora, Spotify, Podbay, iHeart Radio, or wherever you listen to podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsored by: Stallergenes GreerThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University. --- SYNPOSIS The doctors address the trial's practical implications, patient selection, case management, dealing with tumor progression, and the integration of multidisciplinary care. They also emphasize the importance of communication, real-world application of trial protocols, and the potential benefits and challenges of such therapies. --- TIMESTAMPS 00:00 - Introduction03:18 - Discussing the New Indication for Immunotherapy11:42 - Challenges and Practical Implementation22:48 - Managing Tumor Progression: A Case Study28:07 - Exploring Treatment Options: Surgery vs. Chemotherapy36:46 - Operational Challenges and Future Directions43:58 - Concluding Thoughts and Future Directions --- RESOURCES Keynote 689https://www.nejm.org/doi/full/10.1056/NEJMoa2415434

On Tuesday's show: Children at Risk has released its annual list of the top public schools in Houston. The organization's CEO, Bob Sanborn, walks us through the rankings.Also this hour: Houstonians played a big role in the Gemini missions, which were stepping stones in America's 1960s journey to the moon. The program that preceded Apollo is the focus of Jeffrey Kluger's new book, Gemini: Stepping Stone to the Moon, the Untold Story.Then, we visit Texas Children's Hospital to learn about the first immunotherapy center dedicated to fighting pediatric cancer.And, on Veterans Day, we hear local Air Force veteran Ty Mahany's story about an encounter with a World War II veteran and discover what he learned about engaging fellow veterans in conversations about their service.Watch

Send us a textIs your lab truly digitally ready—or just scanning slides?That's the question I unpack in this live discussion from Day 2 of SITC's 40th Anniversary Meeting, joined by David Anderson (Biocare Medical) and Don Ariyakumar (Hamamatsu Photonics). Together, we explore what digital readiness really means for multiplex immunofluorescence (mIF) and how to build reliable, reproducible workflows that scale from research to clinical settings.What We DiscussThe Discovery Funnel I open by situating mIF within the broader discovery funnel: researchers begin with hundreds of biomarkers, narrowing down to focused 4–10 marker panels where true clinical utility begins. But this only works if the lab is digitally prepared from the start—from slide prep to data capture.Defining Digital Readiness David Anderson reframes digital readiness as everything that happens before the scanner turns on:Reagent consistencyAntibody optimizationAutomationStandardized protocols All these elements ensure that downstream AI and image analysis tools work on clean, reproducible data instead of “fixing” noise later.The Pre-Analytical Foundation Don Ariyakumar emphasizes that scanning can't fix variability. If staining or section quality isn't standardized, digitization simply amplifies inconsistencies. True readiness starts at the bench, not the monitor.Integration Across Vendors We also talk about how interoperability between stainers, scanners, and spatial biology software is becoming essential. A disconnected workflow—mixing manual, unaligned steps—adds variables that no algorithm can fully normalize.Lessons from IHC's Evolution The team draws parallels between multiplex IF today and IHC's early days: once complex, now routine. Multiplex IF promises even richer tumor microenvironment insights, but only if standardization and automation catch up to the technology.Beyond the Funnel I revisit the “funnel” metaphor in a new light—arguing that as precision medicine grows, the bottom of the funnel broadens, not narrows. That means more tailored, smaller panels rather than one-size-fits-all assays, and a growing need for efficient, reproducible digital workflows.Key Takeaways“Digital readiness” starts before scanning — with chemistry, automation, and process control.Consistent pre-analytical quality = reproducible, AI-ready data.Interoperability between systems (like Biocare's ONCORE Pro X and Hamamatsu's MoxiePlex) accelerates workflow standardization.Multiplex IF is maturing quickly, just as IHC once did—on its way to becoming a cornerstone of precision pathology.Resources Mentioned

In this episode of the Wise Divine Women podcast, Dana Irvine and Dr. John Oertle discuss the latest advancements in breast cancer research, focusing on recurrence rates, the role of circulating tumor cells, and the importance of optimizing the immune system. Dr John's main goal is to enlighten Americans and people worldwide that there is a groundbreaking study published in Nature is shining a light on a hidden risk: respiratory infections can reawaken dormant breast cancer cells, accelerating recurrence. Read the article and research links They explore the impact of environmental toxins on cancer, the necessity of early detection through testing, and the effects of respiratory infections on cancer patients. The conversation also touches on the role of vaccines in immune response and the potential future of peptides in cancer treatment, emphasizing the need for advocacy in accessing innovative therapies.Envita Medical Center Want to listen to our first episode together? Wise Divine Women podcast, host Dana Irvine speaks with Tammy Morrow and Dr. John Oertle about the intersection of faith, health, and innovative cancer treatmentsTakeawaysRecurrence rates for stage one breast cancer can be as high as 20-30%.Circulating tumor cells can be detected even in early-stage cancers.Optimizing the immune system is crucial for cancer patients.Environmental toxins may trigger cancer development.Testing for circulating tumor cells can aid in early detection.Respiratory infections can impact cancer recurrence and growth.Vaccines may enhance immune response in cancer treatment.Peptides show promise in cancer treatment but require careful dosing.Advocacy for access to innovative treatments is essential.Education and awareness are key for patients in managing their health.Chapters00:00 Introduction to Breast Cancer Research01:04 Understanding Recurrence Rates in Breast Cancer03:51 The Role of Circulating Tumor Cells09:38 Maximizing Outcomes Through Immune System Support17:18 Challenges in Oncology: Insurance and Testing21:20 Environmental Toxins and Cancer Prevention23:43 Impact of Respiratory Infections on Cancer25:15 The Role of IL-6 in Cancer Growth28:25 Monitoring Cancer Recurrence Post-Infection29:37 Vaccines and Immune Response33:14 Immunotherapy and Immune System Dynamics37:45 The Future of Peptides in Cancer Treatment46:05 Access to Preventive HealthcareI hope you enjoyed this episode! Please leave a review and share with friends and family Want to learn more about my offerings? Please visit danairvine.com I invite you to schedule a Soul Session to lern about how we can work together or dive right in and book a Women's Hormone Transformation

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy. Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the treatment in about 25 years. So this is for newly diagnosed women. The very first treatment that they would have, which we call frontline treatment, is a platinum-based chemotherapy. So carboplatin and Paclitaxel are both administered through IV over an hour for carboplatin, about three hours for Paclitaxel. So most women go directly to chemotherapy and then surgery, and then chemotherapy. Some women will go straight to surgery and then have this chemotherapy afterwards."   "Our approach is a DNA-based immunotherapy candidate that we have in Phase 3. We refer to the lead candidate as IMNN-001, and this is a non-viral nanoparticle that is administered directly into the cavity of interest. So, what we call the micro-tumor environment is the peritoneal cavity, where the cancer actually resides, and it's delivered through a catheter. And it basically has a very powerful anti-cancer fighting cytokine, IL-12, that is encoded in this immunotherapy. And it causes the cells that are within each woman's body, both cancer and non-cancer alike, to start producing activities that will help fight these complex cancer cells that exist."  #IMUNON #OvarianCancer #DNABasedImmunotherapy #WomensHealth #CancerAwareness  imunon.com Download the transcript here

Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy. Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the treatment in about 25 years. So this is for newly diagnosed women. The very first treatment that they would have, which we call frontline treatment, is a platinum-based chemotherapy. So carboplatin and Paclitaxel are both administered through IV over an hour for carboplatin, about three hours for Paclitaxel. So most women go directly to chemotherapy and then surgery, and then chemotherapy. Some women will go straight to surgery and then have this chemotherapy afterwards."   "Our approach is a DNA-based immunotherapy candidate that we have in Phase 3. We refer to the lead candidate as IMNN-001, and this is a non-viral nanoparticle that is administered directly into the cavity of interest. So, what we call the micro-tumor environment is the peritoneal cavity, where the cancer actually resides, and it's delivered through a catheter. And it basically has a very powerful anti-cancer fighting cytokine, IL-12, that is encoded in this immunotherapy. And it causes the cells that are within each woman's body, both cancer and non-cancer alike, to start producing activities that will help fight these complex cancer cells that exist."  #IMUNON #OvarianCancer #DNABasedImmunotherapy #WomensHealth #CancerAwareness  imunon.com Listen to the podcast here

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Phil L'Huillier, CEO of Scancell, has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care checkpoint inhibitors, improving duration of response without adding side effects or toxicity. Patient selection in future trials will use a blood test to identify the immune types that can be expected to respond best to the therapy. Phil explains, "Perhaps first and foremost, Scancell is a clinical-stage company developing novel active immunotherapies for patients. And our objective for patients is to pick up the patients that are unresponsive to current therapies or that respond for a short period of time to improve the overall survival through developing therapies that give a good duration of response, potent immune responses, but are also safe for patients." "Perhaps before I share results from the studies, I should step back a little bit and just tell you about the platform and the product that the data has arisen for. At Scancell, we're developing these off-the-shelf. The data that we're about to talk about comes from our lead program, which is an off-the-shelf DNA immunotherapy called Immunobody, that's the name that we use for it. And it's different from the personalized therapies, the personalized vaccines that require an individual to give a tumor sample. And then there's sequencing and manufacturing for the individual there. This is off the shelf." #Scancell #Immunobody #Immunotherapy #Cancer #Oncology #Melanoma #Biotech scancell.co.uk Listen to the podcast here

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Want to heal your child's eczema without steroids and save $200 this week? Click here to get started → EczemaKids.com Use code EPISODE200 to get $200 off the Eczema Elimination Method.... the COMPLETE eczema-reversal system that actually works. This offer is good for one week only and ends Tuesday, November 4th, 2025. If your child's ever had an allergy test hoping for answers, only to walk out more confused or flaring, this episode is for you. As we celebrate 200 episodes (and my birthday week!), I'm breaking down what allergy tests actually measure, why kids with eczema often react badly, and how to tell the difference between true, serious IgE allergies and immune overload. We'll talk about why scratch tests and immunotherapy often do more harm than good for eczema families, what to do if your child already flared after testing, and how to start healing their skin and gut from the inside out.

While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.---SYNPOSISThe doctors discuss the trial details, FDA approval, and practical challenges of integrating this new paradigm into clinical practice. The conversation covers critical points such as the necessity of CPS score testing, timely drug administration, patient monitoring, and the importance of collaboration among multidisciplinary teams.---TIMESTAMPS00:00 - Introduction02:18 - Keynote-689 Trial Explained04:42 - Implementation Challenges and Strategies06:40 - Practical Considerations for CPS Testing13:59 - Case Studies and Real-World Applications30:48 - Future Directions and Final Thoughts---RESOURCESKeynote-689https://www.nejm.org/doi/full/10.1056/NEJMoa24154342004 Cisplatin Phase III Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa032646

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.